Mr Samuel Richardson

Samuel obtained his MSc in Microbiology and Infection from the University of Birmingham in 2017 and went on to work in Public Health England’s biosafety group. Moving to the National Institute for Biological Standards and Control in 2019, he was involved in the development of WHO International Standards for antibodies to SARS-CoV-2, MERS-CoV and Lassa Fever virus.

Samuel joined the Pirbright institute in 2021 as part of the newly established CL3 team, set up to increase the institute’s capacity for working on projects involving ACDP Hazard Group 3 viruses. His current areas of interest include research into SARS-CoV-2 and antiviral drug resistance mechanisms of avian influenza virus.